Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$734M |
| 2 |
Adobe
ADBE
|
+$488M |
| 3 |
Merck
MRK
|
+$443M |
| 4 |
Tesla
TSLA
|
+$366M |
| 5 |
AGN
Allergan plc
AGN
|
+$315M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$682M |
| 2 |
Perrigo
PRGO
|
+$585M |
| 3 |
Gilead Sciences
GILD
|
+$556M |
| 4 |
EMC
EMC CORPORATION
EMC
|
+$432M |
| 5 |
Morgan Stanley
MS
|
+$401M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.94% |
| 2 | Consumer Discretionary | 14.99% |
| 3 | Communication Services | 11.27% |
| 4 | Technology | 9.94% |
| 5 | Financials | 9.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Verastem
VSTM
$528M
| $5.72M | 0.01% |
41,830
+163
| +0.4% | +$21.4K |
|
|
HSTO
502
DELISTED
Histogen Inc. Common Stock
HSTO
| $5.47M | 0.01% |
4,238
+13
| +0.3% | +$20.8K |
|
503
Marcus & Millichap
MMI
$1.2B
| $5.37M | 0.01% |
+360,630
| New | +$5.1M |
|
504
Essential Utilities
WTRG
$11.5B
| $5.29M | 0.01% |
224,016
-704,969
| -76% | -$17.2M |
|
|
STAY
505
DELISTED
Extended Stay America, Inc. Paired Share Unit
STAY
| $5.08M | 0.01% |
+193,387
| New | +$4.77M |
|
|
AENZ
506
DELISTED
Aenza S.A.A.
AENZ
| $4.89M | ﹤0.01% |
76,824
| – | – |
|
|
BRLI
507
DELISTED
BIO-REFERENCE LABS INC-NEW-
BRLI
| $4.65M | ﹤0.01% |
181,970
-1,682,153
| -90% | -$51.8M |
|
|
TEN
508
DELISTED
Tenneco Inc. Class A Voting Common Stock
TEN
| $4.64M | ﹤0.01% |
82,068
-34
| -0% | -$1.85K |
|
|
AERI
509
DELISTED
Aerie Pharmaceuticals
AERI
| $4.61M | ﹤0.01% |
+256,864
| New | +$3.35M |
|
510
IQVIA
IQV
$40.7B
| $4.59M | ﹤0.01% |
99,145
-502,607
| -84% | -$22M |
|
|
TRNX
511
DELISTED
TORNIER N V SHARES (NLD)
TRNX
| $4.47M | ﹤0.01% |
237,943
+894
| +0.4% | +$16.9K |
|
512
InspireMD
NSPR
$31.4M
| – | – |
0
| – | – |
|
|
MGLN
513
DELISTED
Magellan Health Services, Inc.
MGLN
| $4.02M | ﹤0.01% |
67,087
-7,315
| -10% | -$437K |
|
|
SUSQ
514
DELISTED
SUSQUEHANNA BANCSHARES INC
SUSQ
| $3.73M | ﹤0.01% |
290,709
+50,186
| +21% | +$623K |
|
515
CSX Corp
CSX
$94B
| $3.62M | ﹤0.01% |
377,796
+25,695
| +7% | +$230K |
|
516
Webster Financial
WBS
$12.3B
| $3.61M | ﹤0.01% |
115,841
+22,793
| +24% | +$648K |
|
517
DuPont de Nemours
DD
$18.6B
| $3.55M | ﹤0.01% |
31,572
-695
| -2% | -$71.2K |
|
518
Altria Group
MO
$125B
| $3.52M | ﹤0.01% |
+91,581
| New | +$3.38M |
|
519
Eli Lilly
LLY
$1.08T
| $3.49M | ﹤0.01% |
68,383
+6,147
| +10% | +$308K |
|
520
Meritage Homes
MTH
$4.78B
| $3.48M | ﹤0.01% |
144,978
+17,944
| +14% | +$389K |
|
521
Macy's
M
$6.51B
| $3.44M | ﹤0.01% |
64,479
+1,323
| +2% | +$64.1K |
|
522
Norfolk Southern
NSC
$75.4B
| $3.42M | ﹤0.01% |
36,812
+9,622
| +35% | +$826K |
|
523
Rogers Corp
ROG
$2.08B
| $3.38M | ﹤0.01% |
55,040
-6,750
| -11% | -$407K |
|
|
CB
524
DELISTED
CHUBB CORPORATION
CB
| $3.35M | ﹤0.01% |
34,668
-894
| -3% | -$83.4K |
|
525
Chevron
CVX
$382B
| $3.33M | ﹤0.01% |
26,630
-686
| -3% | -$82.9K |
|
Similar funds
Jennison Associates's Q4 2013 Portfolio in Review
As of Q4 2013, Jennison Associates held 759 positions worth $102B, up 6.9% from $95.4B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Jennison Associates's Q4 2013 filing shows 79 new, 184 increased, 411 reduced and 54 closed positions. Its largest new stake was Allergan plc: 2,016,619 shares worth $339M. The largest sale was UnitedHealth, an estimated $682M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 17% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q4 2013 buy was Allergan plc: 2,016,619 shares worth $339M.
- Jennison Associates added most to Bristol-Myers Squibb in Q4 2013, an estimated $734M increase.
- Jennison Associates's biggest Q4 2013 reduction was UnitedHealth, cutting an estimated $682M.
- Jennison Associates fully exited Perrigo in Q4 2013, selling an estimated $585M.
- Jennison Associates's ten largest holdings make up 20% of its $102B portfolio in Q4 2013.
- Jennison Associates opened 79 new positions and closed 54 in Q4 2013.
- Jennison Associates's portfolio value rose 6.9% quarter-over-quarter to $102B.
Based on Jennison Associates's 13F filing for Q4 2013, filed 10 Feb 2014.